Marijuana Penny Stocks With so much excitement building around the potential breakout of a legal recreational pot business open for investment,

Two Medical Marijuana Penny Stocks to Watch Out for in the Wake of Complete Weed Legalization in 2017

Weed Legalization in the U.S.

Marijuana Penny Stocks With so much excitement building around the potential breakout of a legal recreational pot business open for investment,

Marijuana Penny Stocks With so much excitement building around the potential breakout of a legal recreational pot business open for investment, the very profitable medical marijuana business usually gets overlooked. For those investing in marijuana stocks, that’s a big mistake. The top medical marijuana penny stocks have the potential to provide even more lucrative returns.

It’s important to remember that the path to weed legalization in the U.S. is on two different tracks for medicinal and recreational marijuana. While recreational marijuana is gaining steam across the U.S., with Nevada being the latest state to enshrine the legal usage of marijuana into law, it’s still a far ways behind on medicinal marijuana.



 Marijuana Penny Stocks

While the majority of Americans do believe that marijuana should be legalized, both federally and statewide, the process is slow-going in terms of mass legalization. Sure, the most populous state in the country, California, has legal weed, as well as several other states and D.C., but that’s still nowhere near full acceptance. Not to mention that the drug is still illegal federally, meaning that technically, national agents could come in and close down every single recreational marijuana dispensary in the country.

You see, under the Obama administration, while not directly endorsing marijuana use, the former president and his team tacitly condoned states moving towards more legalization as federal agents stayed out of the states’ way once legislation was passed.

With that blow coming towards the Sessions crusade against marijuana and Booker pushing legislation, it was a great past week for the marijuana industry.

So with that good new coming in spades, let’s take a look at the marijuana stock list that shows two medical marijuana stocks I think are two of the top medical marijuana penny stocks.

Top Medical Marijuana Penny Stocks

weed3

Chart courtesy of StockCharts.com

Aphria Inc (TSE:APH)

Aphria has a lot going for it. It’s based out of Canada, which is set to legalize all forms of marijuana use by summer 2018. It has a novel way of growing its product—through greenhouses—that will lend it a competitive advantage. And it already supplies a good portion of medical marijuana to the market.

Canopy Growth Crop (TSE:WEED)

As the biggest player in the marijuana market, with a market cap of nearly $1.5 billion, it’s easy to see why such a huge and respected player in the market would be a solid penny stock.

In fact, it’s quite surprising that WEED stock is among the top medical marijuana penny stocks considering its size, but with the value of its shares well below $10.00, WEED stock is still in the penny stock phase of growth.

 

Like up on FACEBOOK


logo



Pharmaceuticals  stocks ( CGC)  ( JNJ ) ( MRK ) ( GSK ) ( celg )  ( gild )

 


 



 Digipath Receives Recreational Testing License  (DIGP), an independent testing laboratory and media firm focused on the burgeoning

Digipath, Inc. (DIGP) Receives Recreational Testing License and Renews Medical License

Digipath Receives Recreational Testing License and Renews Medical License as Retail Cannabis Market Launches in Nevada

 Digipath Receives Recreational Testing License  <span data-recalc-dims=(DIGP), an independent testing laboratory and media firm focused on the burgeoning" width="300" height="172" srcset="https://i1.wp.com/investorsbuz.com/wp-content/uploads/2017/07/94753.jpg?resize=300%2C172 300w, https://i1.wp.com/investorsbuz.com/wp-content/uploads/2017/07/94753.jpg?w=500 500w" sizes="(max-width: 300px) 100vw, 300px" />

FOREX  INVESTORS PRESS RELEASE    Digipath Receives Recreational Testing License  (DIGP), an independent testing laboratory and media firm focused on the burgeoning cannabis market, is pleased to announce that it has both received its recreational testing license and renewed its existing medical testing license alongside the launch of the highly anticipated retail cannabis market in Nevada which began on July 1, 2017.

DigiPath, Inc., through its subsidiary, DigiPath, Corp., creates and markets innovative and reliable digital pathology solutions that empower private and academic institutions with the ability to create, store, manage, analyze, and correlate data collected through virtual microscopy. DigiPath, Inc. digital pathology portfolio includes PathScope(TM), PathCloud(TM), PathReview(TM), and PathConsult(TM) digital platforms to share and store archive tissue images. DigiPath, Inc. is expanding into new lines of business associated with the research, development, licensing and operation of botanical and nutrapharmaceutical products and services. (PRNewsFoto/Digipath, Inc.)

Nevada’s medical cannabis market currently serves just over 28,000 patients that use the plant and its derivative products for the treatment of a variety of maladies. However, with the launch of the retail marijuana market, anyone over the age of 21 with valid identification can purchase cannabis products. This opens the market to a much larger portion of Nevada’s 2 million residents over the age of 21, as well as a significant segment of the more than 42 million tourists and convention goers that visit the state annually.



Digipath Receives Recreational Testing License

The Nevada Dispensary Association estimated that statewide adult-use sales were between $3 to $5 million in the first weekend. As sales continue to rise, suppliers of cannabis products will be moving rapidly to meet the increased demand, necessitating a much larger demand for the laboratory testing of these products. Similar market shifts occurred with the launch of adult-use cannabis markets in Colorado, Oregon, and Washington State, and Nevada is expected to be one of the largest adult-use markets in the United States by the end of 2018.

Todd Denkin, President of Digipath, commented, “It’s really exciting to be a part of history as Nevadans get what they voted for in 2016. The entire medical marijuana community has been working overtime to satisfy this new retail customer base. With the highest capacity and the fastest turnaround time of any lab in Nevada, Digipath Labs is ready for the onslaught of both retail and medical cannabis and cannabis based products.”

About Digipath, Inc.
Digipath, Inc. is an independent cannabis testing and media firm that supports the cannabis industry’s best practices for reliable testing and delivers cannabis news coverage and education about the cannabis industry. Digipath’s two business units are Digipath Labs and TNM News Corp. Digipath Labs™ is working to set the industry standard for testing all forms of cannabis-based products using FDA-compliant laboratory equipment and proprietary standard operating procedures (SOP) to ensure product safety and efficacy. TNM News Corp. has pioneered a cannabis-focused news network, The National Marijuana News, which delivers news, interviews, and education on all things cannabis.Like up on FACEBOOK


logo



Pharmaceuticals  stocks ( CGC)  ( JNJ ) ( MRK ) ( GSK ) ( celg )  ( gild )



Medical Marijuana Inc CFN Media Group, the leading creative agency and digital media network dedicated to legal cannabis, announces the publication of an article on Medical Marijuana Inc.’s ( OTC PINK : MJNA ) new HempMeds®

Medical Marijuana Inc.’s (MJNA) Opens Office in Mexico with Leading Advocate

HempMeds Opens Office in Mexico with Leading Advocate

Medical Marijuana Inc CFN Media Group, the leading creative agency and digital media network dedicated to legal cannabis, announces the publication of an article on Medical Marijuana Inc.’s ( OTC PINK : MJNA ) new HempMeds®

FOREX INVESTORS  PRESS RELEASE  Medical Marijuana Inc CFN Media Group, the leading creative agency and digital media network dedicated to legal cannabis, announces the publication of an article on Medical Marijuana Inc.’s ( OTC PINK : MJNA ) new HempMeds® office in Mexico and why it’s a significant development for the company.
Mexico’s Progressive Stance

Mexico has been historically opposed to marijuana legalization thanks to the United States’ War on Drugs since the 1970s. Since the 1990s, Mexican drug cartels have grown in power following the demise of the Colombian Cali and Medellin cartels. Analysts estimate that wholesale earnings from illicit drug sales range from $13.6 billion to $49.4 billion each year, which is on par with multinational tobacco companies that earn about $30 billion per year.



Medical Marijuana Inc

 

After many US states began taking a more progressive approach by legalizing marijuana, Mexico’s Senate passed a bill legalizing medical marijuana in December 2016. The country’s lower house in parliament followed suit by passing the bill in late-April with an overwhelming 374-7 vote. President Enrique Pena Nieto officially signed the bill into law last month, which makes medical marijuana available and legal throughout the country.

The Health Ministry will now be tasked with creating regulations around the use of medical marijuana, including the production of cannabinoid-based pharmaceuticals. In the meantime, consumers will be permitted to legally purchase cannabinoid products that contain 1% or less tetrahydrocannabinol (THC), while companies will be permitted to cultivate cannabis for medical and scientific purposes without being punished by law.

Establishing a Footprint

Medical Marijuana Inc. has been a pioneer in Mexico’s cannabinoid industry. Last year, the company secured the first import permit for RSHO-X™ — a non-psychoactive cannabidiol (CBD) hemp oil for patients suffering from severe seizures — from COFEPRIS — the country’s health authority. Many other patients have since secured import rights for the CBD oil that has shown tremendous promise in helping patients overcome severe seizures.

Earlier this year, the company began groundbreaking new studies of its RSHO-X™ in Mexico under the direction of pediatric neurologist Dr. Saul Garza Morales. The results of these studies showed a 50% or greater reduction in seizures in 33 of 39 patients, while over half of patients achieved an overall 75% reduction in seizures. But, perhaps the most striking result was the 100% seizure relief experienced by about 17% of patients in the study.

HempMeds® is expanding its presence with the opening of its first office in Monterrey, Nuevo Leon, Mexico, as demand continues to grow for RSHO-X™. The new office will be managed by medical cannabis activist and Por Grace Foundation founder Raul Elizalde and act as a hub for the sales, marketing, and distribution of RSHO-X™ to patients in Mexico. The company also aims to further its efforts to push for cannabis reform in the country. Major news outlets attended the inauguration including Forbes Mexico, HuffPost, and El Financiero among others.

Mr. Elizalde’s daughter, Grace, was the first Mexican patient to gain legal access to CBD oil, for the control of her seizures. He is recognized throughout the country for his determined efforts to expand access for more patients, and even joined President Nieto on stage in April as he announced the country’s intentions to legalize medical marijuana. His tireless dedication to the cause, and the resulting renown, should benefit the company as it grows its footprint throughout Mexico.

For more information, visit the company’s website or CannabisFN’s company profile.Like up on FACEBOOK


logo



Pharmaceuticals  stocks ( CGC)  ( JNJ ) ( MRK ) ( GSK ) ( celg )  ( gild )



BUZ INVESTORS PRESS RELEASE ZDPY Eliminates Current Debt Zoned Properties, Inc. (ZDPY), a strategic real estate development firm whose primary mission is to identify, develop, and lease sophisticated, safe, and sustainable properties

Zoned Properties, Inc. (ZDPY) Establishes Corporate Headquarters at Medical Marijuana Business Park in Tempe

Zoned Properties’ Primary Arizona Tenant Establishes Corporate Headquarters at Medical Marijuana Business Park in Tempe

New Lease Agreement Adds Additional 2,500 square feet of Leased Space

BUZ INVESTORS PRESS RELEASE ZDPY Eliminates Current Debt Zoned Properties, Inc. <span data-recalc-dims=(ZDPY), a strategic real estate development firm whose primary mission is to identify, develop, and lease sophisticated, safe, and sustainable properties" width="300" height="168" srcset="https://i1.wp.com/investorsbuz.com/wp-content/uploads/2017/04/1ZDPY.banner-1-680x380.jpg?resize=300%2C168 300w, https://i1.wp.com/investorsbuz.com/wp-content/uploads/2017/04/1ZDPY.banner-1-680x380.jpg?resize=680%2C380 680w" sizes="(max-width: 300px) 100vw, 300px" />

FOREX INVESTORS   PRESS RELEASE   Zoned Properties, Inc. (ZDPY), a strategic real estate development firm whose primary mission is to identify, develop, and lease sophisticated, safe, and sustainable properties in emerging industries, including the licensed medical marijuana industry, today announced it has signed a five-year commercial lease agreement with its primary tenant in Arizona, Hana Meds, to establish their Corporate Headquarters at its Medical Marijuana Business Park in Tempe, Ariz.

The renovated corporate suite includes 2,500 square feet of office and conference space, which will provide a cornerstone to base their corporate operations. Hana Meds will become the premier, anchor tenant for the property. The licensed medical marijuana tenant plans to establish a comprehensive, vertically-integrated operation at the Medical Marijuana Business Park, including all stages of medical marijuana business activities.




Zoned Properties, Inc

 

“We are pleased to further expand our relationship with Hana Meds by providing newly renovated corporate office space that is conveniently located next to their licensed medical marijuana facilities. We are inspired by our tenant’s strategic goals to capture market share by controlling their own standards of product development and distribution within every aspect of the vertically-integrated business process,” commented Bryan McLaren, Chief Executive Officer of Zoned Properties. “The time and effort our team has invested in developing this property as a state-of-the-art, sustainable facility has helped to persuade our tenant to establish its corporate headquarters at the Business Park, validating proof of concept for the property. This agreement demonstrates our mutual commitment to the City of Tempe for economic development as the licensed medical marijuana industry continues its rapid expansion.”

Under the terms of the five-year lease agreement, which commences on July 1, 2017, monthly rental payments of $1,800 per month will begin on October 1, 2017. The tenant expects to generate a significant number of new jobs as their operations continue to grow.

About Zoned Properties, Inc. (ZDPY):

Zoned Properties is a strategic real estate development firm whose primary mission is to identify, develop, and lease sophisticated, safe, and sustainable properties in emerging industries, including the licensed medical marijuana industry. The Company acquires commercial properties that face unique zoning challenges and identifies solutions that can potentially have a major impact on the cash flow and property value. Zoned Properties targets commercial properties that can be acquired and re-zoned for specific purposes. Zoned Properties does not grow, harvest, sell or distribute cannabis or any substances regulated under United States law such as the Controlled Substances Act.

Like up on FACEBOOK


logo



Pharmaceuticals  stocks ( CGC)  ( JNJ ) ( MRK ) ( GSK ) ( celg )  ( gild )




Buz Investors Canabo Medical Inc. Opens New Clinic i- Canabo Medical Inc. (TSX VENTURE: CMM) (OTCQB: CAMDF) ("Canabo" or the "Company") is pleased to announce it has opened a clinic in Chilliwack, British Columbia

Canabo Medical Inc. (CMM.V) Opens Second Nova Scotia Clinic

Canabo Opens Second Nova Scotia Clinic and Announces Appointment of Garry Stewart as Chief Financial Officer

Canabo Medical Inc. (TSX VENTURE: CMM) <span data-recalc-dims=(CAMDF) (“Canabo” or the “Company”) is pleased to announce it has opened its second clinic in Nova Scotia for a total of 22 clinics and partner clinics nationwide" width="300" height="300" srcset="https://i2.wp.com/investorsbuz.com/wp-content/uploads/2017/03/iszoKIoU.png?resize=300%2C300 300w, https://i2.wp.com/investorsbuz.com/wp-content/uploads/2017/03/iszoKIoU.png?resize=150%2C150 150w, https://i2.wp.com/investorsbuz.com/wp-content/uploads/2017/03/iszoKIoU.png?resize=65%2C65 65w, https://i2.wp.com/investorsbuz.com/wp-content/uploads/2017/03/iszoKIoU.png?w=450 450w" sizes="(max-width: 300px) 100vw, 300px" />

BUZ INVESTORS  PRESS RELEASE  Canabo Medical Inc. (TSX VENTURE: CMM) (CAMDF) (“Canabo” or the “Company”) is pleased to announce it has opened its second clinic in Nova Scotia for a total of 22 clinics and partner clinics nationwide. The new clinic, located in Wolfville, Nova Scotia is now accepting referrals. As the second clinic for the province of Nova Scotia, this opening represents a broadening of Canabo’s national clinic footprint.
As previously discussed on June 5 in the Company’s Corporate Update, the clinic reports new patient volumes continue at record levels.

Dr. Neil Smith, Executive Chairman of Canabo Medical Inc. stated, “As explained in our June 5th Corporate Update we reiterate, there was no fundamental reason for the sharp decline in our share price during May. The Company’s operating fundamentals and growth trajectory remain strong.”

Canabo also announces today the appointment of Mr. Garry Stewart as Chief Financial Officer.




Canabo Medical

 

Mr. Stewart is a Chartered Professional Accountant who brings over 25 years of professional experience to the role. Prior to joining Canabo, Mr. Stewart served as CFO, Vice President Finance at TAR Investments Ltd., including Datarite Ltd. and Atlantic Business Interiors Ltd.

Mr. Stewart replaces Mr. Rob Randall as Chief Financial Officer. Mr. Randall is leaving Canabo to focus on his other CFO roles but will continue to support and assist Mr. Stewart during the transition. John Philpott, President & CEO of Canabo, commented, “I would like to thank Rob for his service to Canabo. He played a key role in the RTO transaction as well as the growth of the business. We wish him well in his future endeavours.”

About the Company

Canabo wholly owns and operates Cannabinoid Medical Clinics, or CMClinics, Canada’s largest physician led referral-only clinics for medical cannabis. Established in 2014, Canabo now has 22 clinics across Canada, with additional locations planned to open in 2017. Canabo operates referral-only medical clinics dedicated to evaluating the suitability of prescribing, and monitoring cannabinoid treatments for patients suffering from chronic pain and disabling illnesses. Clinics operated by Canabo are staffed by physicians and qualified health care practitioners specifically trained to assess patient suitability for cannabinoid treatment, recommend treatment regimes, and monitor treatment progress.

Forward-Looking Statements

Except for historical information, this press release contains forward-looking statements, which reflect Canabo Medical Inc.’s current expectations regarding future events. These forward-looking statements involve known and unknown risks and uncertainties that could cause Canabo’s actual results to differ materially from those statements. Those risks and uncertainties include, but are not limited to, the Company’s ability to access capital, the successful and timely completion of opening clinics, regulatory changes, competition, approvals and other business and industry risks.

The forward-looking statements in this press release are also based on a number of assumptions which may prove to be incorrect. Forward-looking statements contained in this press release represent views only as of the date of this release and are presented for the purpose of assisting potential investors in understanding Canabo’s business and may not be appropriate for other purposes. Canabo does not undertake to update forward-looking statements, whether written or oral, that may be made from time to time by or on its behalf, except as required under applicable securities legislation. Investors are cautioned not to rely on these forward-looking statements and are encouraged to consult with a professional investment advisor.

Readers are cautioned that the foregoing list is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.

Like up on FACEBOOK


logo



Pharmaceuticals  stocks ( CGC)  ( JNJ ) ( MRK ) ( GSK ) ( celg )  ( gild )




Matica Accelerates Construction Plans   Matica Enterprises Inc. (MMJ–CSE) (39N – Frankfurt) (MQPXF – OTC PINK) (“Matica” or the “Company”) is pleased to announce that it plans to undertake a non-brokered private placement

Matica Accelerates Construction Plans for Dorval Medical Marijuana Facility

Matica Accelerates Construction Plans for Dorval Medical Marijuana Facility

 

Matica Accelerates Construction Plans   Matica Enterprises Inc. (MMJ–CSE) (39N – Frankfurt) (MQPXF – OTC PINK) (“Matica” or the “Company”) is pleased to announce that it plans to undertake a non-brokered private placement

BUZ INVESTORS  PRESS RELEASE Matica Accelerates Construction Plans   Matica Enterprises Inc. (MMJ–CSE) (39N – Frankfurt) (MQPXF – OTC PINK) (“Matica” or the “Company”) is pleased to announce that it plans to undertake a non-brokered private placement of up to twenty million (20,000,000) units (the ” Units “) to raise gross proceeds of up to $1,000,000 (the ” Offering “). The Units will be offered at a price of $0.05, with each Unit consisting of one common share and one common share purchase warrant. Each warrant will be exercisable to acquire one common share of the Company at a price of $0.10 for a period of eighteen months.

RoyalMax Biotechnology Canada Inc. (“RoyalMax”) has received a “request for readiness” letter which Health Canada issued in June.  These letters along with the improvements to the ACMPR application process announced in late May are a positive development for RoyalMax and the industry as a whole.  As such, Management has planned to accelerate the construction schedule and has therefore made the decision to raise funds now for early completion of the RoyalMax facility in Dorval, Quebec. Matica is striving to have RoyalMax become the second licensed producer in the province of Quebec.




Matica Accelerates Construction Plans

Proceeds from the Offering will be used for build out of the Dorval facility and general working capital. All securities purchased under this Offering will be subject to a four month hold period. Finders’ fees may be payable on a portion of the Offering in accordance with the policies of the CSE. Completion of the Offering is subject to the acceptance of the CSE.

About Matica

Matica has an agreement with RoyalMax Biotechnology Canada Inc. (“RoyalMax”) for Matica to become a majority owner (70%) of the late stage applicant under the Access to Cannabis for Medical Purposes Regulation (“ ACMPR ”). Through RoyalMax, Matica is diligently moving forward with its application to become a Licensed Producer of medical marijuana under ACMPR.   With permits in place, Matica has started to prepare the facility for retrofitting.

For more information on Matica please visit the website at: www.maticaenterprises.com .

Like up on FACEBOOK


logo



Pharmaceuticals  stocks ( CGC)  ( JNJ ) ( MRK ) ( GSK ) ( celg )  ( gild )




Buz Investors Bittium exhibits renewed Bittium Tough Mobile – Bittium exhibits its innovative products and mobile security solutions at the British APCO exhibition to be held in Telford, United Kingdom, March 21 – 22. The event is directed

Bittium and Coronaria co-operate to further develop medical remote diagnostic services

Bittium and Coronaria co-operate to further develop medical remote diagnostic services

Bittium and Coronaria co-operate to further develop medical remote diagnostic services

Bittium sells its medical remote diagnostic services business to Coronaria Analyysipalvelut Oy and acquires 25 percent of the shares in Coronaria Analyysipalvelut Oy

BUZ INVESTORS  PRESS RELEASE  remote diagnostic services Bittium Medanalytics Oy, part of Bittium group, and Coronaria Hoitoketju’s subsidiary Coronaria Analyysipalvelut Oy, have today signed agreements according to which Bittium Medanalytics Oy sells its remote diagnostic service business to Coronaria Asiakaspalvelut Oy. According to the agreement Bittium supplies its web-based service kardiolog.fi used in monitoring cardiac abnormalities to Cornaria’s use. Kardiolog.fi service is used by more than 70 Finnish health centers and private medical centers. The net sales of Bittium Medanalytics Ltd in 2016 was EUR 0.4 million.

Further, Bittium Technologies Ltd, part of Bittium group, has acquired 25 percent of the shares in Coronaria Analyysipalvelut Oy. Through this joint ownership Bittium and Coronaria aim at gaining synergies from Bittium’s device and system development and the interfaces formed by Coronaria’s clinical medicine and services.

“This co-operation agreement with Coronaria provides us with a large network of doctors and specialists to support our medical technology development. Bittium has over 30 years of experience in radio and biosignal measuring. We believe that through this cooperation we are able to improve the healthcare services by developing even more advanced systems and devices. Through this business transaction a significant amount of out-of-hospital biosignal measurements in Finland will use Bittium’s technology in the future” says Hannu Huttunen, CEO of Bittium Corporation.




remote diagnostic services 

 

Coronaria Analyysipalvelut Oy provides biosignal measurement and web-based remote diagnostic services in Finland and its customers are private medical centers, occupational healthcare doctors and hospitals. Coronaria provides approximately 25 000 diagnostic reports per year.

”Cooperation with Bittium is a significant step for Coronaria. We believe that by combining Bittium’s technology competence and Coronaria’s exceptionally wide industry knowhow we are together able to provide high-quality, easy-to-use and secure service solutions for our customers’ everyday life” says Ulla Näpänkangas, Managing Director of Coronaria Analyysipalvelut Oy.

The sale of the services business and share purchase agreement have no significant impact on Bittium Corporation’s operating result outlook for 2017 published in the Financial Statement Bulletin 2016 on February 20, 2017. The parties have agreed that the value of the transaction will not be published.

In its Medical Technologies product and services area Bittium provides among others Faros product family, focused on ECG recording and remote monitoring, NeurOne products focusing on measuring the electrical activity of the brain, and BrainStatus, a disposable quick EEG measuring headband used in emergency and intensive primary care to diagnose for example epileptic seizures and brain stroke, and other healthcare technology products. Bittium continues to develop these products further targeting to grow its product and service offering to healthcare and homecare markets.

Like up on FACEBOOK


logo

Market quotes are powered by
TradingView.com



Tech Stocks ( GOOG)   (MSFT ) ( AAPL ) (BBRY ) ( gopro )  ( WDC )




BUZ INVESTORS Beleave Obtains ACMPR Licence Beleave Inc. ("Beleave" or the "Company") (CSE:(BE)(CSE:BE.(CN) (CNSX:(BE) is pleased to announce that its wholly

Beleave Obtains ACMPR Licence to Cultivate Medical Cannabis

PRESS RELEASE|Chart | Calendar   | TRADE NOW | CANNABIS

Beleave Obtains ACMPR Licence to Cultivate Medical Cannabis

 

 

BUZ INVESTORS  Beleave Obtains ACMPR Licence   Beleave Inc. (“Beleave” or the “Company”) (CSE:(BE)(CSE:BE.(CN) (CNSX:(BE) is pleased to announce that its wholly-owned subsidiary, First Access Medical Inc. (“FAM”), has been granted a licence to cultivate medical cannabis pursuant to the Access to Cannabis for Medical Purposes Regulations (the “ACMPR”).

“We are ecstatic to have achieved our goal of becoming a licensed producer,” commented Beleave CEO Roger Ferreira. “We have remained diligent and focused throughout the process and understand that this is just the beginning of a much bigger plan and vision for Beleave. We remain committed to building a strong foundation of research expertise that we hope will translate into the cultivation of exceptional products for qualified Canadians. Finally, we would like to thank all of our stakeholders for their patience and support over the past three years. We very much look forward to growing with you.”

Beleave Obtains ACMPR Licence  

About Beleave

Beleave Inc. is a biotech company and Beleave’s wholly-owned subsidiary FAM is a licensed producer pursuant to the ACMPR. Beleave’s purpose-built facility is located in Hamilton, Ontario.

Forward-Looking Statements

This news release contains forward-looking information. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking information. Although the Company believes that the expectations and assumptions on which the forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because the Company can give no assurance that they will prove to be correct. These risks and uncertainties include, but are not limited to, the Company’s ability to satisfy the conditions associated with its cultivation licence, the Company’s ability to obtain a sales licence and the related timing considerations, the availability of further financing, consumer interest in its products, competition, regulation, operational and technological risks, and anticipated and unanticipated costs and delays. Since forward-looking information addresses future events and conditions, by its very nature it involves inherent risks and uncertainties. This information speak only as of the date of this news release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents, which can be found under the Company’s profile on www.sedar.com.

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 3741
Compare: NAS:(PULM), NAS:(TTNP), NAS:(CUR), NAS:(XOMA), OTCPK:(AQBT), NAS:(TRIL), OTCPK:(ANTB), AMEX:(AMPE), AMEX:(NBY), NAS:(OVAS), NAS:(ONS), OTCPK:(PMCB), OTCPK:(IGXT), NAS:(PBMD), OTCPK:(DYAI), OTCPK:(GRPOF), OTCPK:(VBIO), OTCPK:(FENCF), NAS:(CLBS), NAS:(ITEK) » details
Traded in other countries: BE.Canada, 4B9.Germany,
Headquarter Location: Canada

Beleave Inc is a biotech company focused on the production of medical marijuana in Canada. The Company is engaged in the development of patents through research with Canadian institutions and R&D of smoke harm reduction products.

Like up on FACEBOOK


logo



Pharmaceuticals  stocks ( CGC)  ( JNJ ) ( MRK ) ( GSK ) ( celg )  ( gild )

BUZ INVESTORS PRESS RELEASE Bittium Faros ECG-measuring devices’ built-in algorithms for detection of arrhythmias have received medical device approval in Europe.

Bittium Faros ECG-measuring devices’ arrhythmia detection algorithms received medical device approval in Europe

Chart | Calendar   | TRADE NOW | Bittium

Bittium Faros ECG-measuring devices’ arrhythmia detection algorithms received medical device approval in Europe

 

Bittium Faros™ ECG-measuring devices’ arrhythmia detection algorithms received medical device approval in Europe

 

BUZ INVESTORS  PRESS RBUZ INVESTORS PRESS RELEASE Bittium Faros ECG-measuring devices’ built-in algorithms for detection of arrhythmias have received medical device approval in Europe. ELEASE  Bittium Faros ECG-measuring devices’ built-in algorithms for detection of arrhythmias have received medical device approval in Europe. The algorithms can be used to automatically identify sequences from the heart measurement data that include atrial fibrillation, tachycardia, bradycardia, and pauses in the operation of the heart. Early detection of atrial fibrillation can be used to predict the risk of stroke and to prevent its emergence with timely treatment initiation. These new medical device approved algorithms for detection of arrhythmias are available now with Faros ECG-measuring devices.

The new functions allow focusing only on the interesting events even in measurements that last for several days or weeks. In remote monitoring applications Faros devices’ arrhythmia detection algorithms help health care providers to react faster to changes in patients’ state of health. Faros technology is also used in Holtering as well as in group monitoring in cardiac rehabilitation.




Bittium Faros

>>>TRADE NOW<<<

Faros product family

Faros is a versatile ECG device that is used for early detection of cardiac abnormalities in everyday life. Faros is ultra-small and lightweight, which enables precise long-term full disclosure ECG measurements for long-term Holtering, cardiac event monitoring, mobile cardiac telemetry and assessing autonomic nervous system functioning.

The Faros outpatient monitoring solutions include several software options for cardiac monitoring. The built-in arrhythmia detection algorithms of the Faros device are used for event recording and mobile event monitoring that enable earlier repatriation of patients and even better ability to react to potentially emerging arrhythmias faster. The new, innovative and sophisticated Holter analysis software increases the accuracy and speeds up the analyzing work significantly.

Faros Cardiac Rehab is a solution for cardiac rehabilitation real-time monitoring for up to 16 patients simultaneously. The system offers safety and efficiency for cardiac rehabilitation by showing each patient’s heart rate, ECG and changes in ST-segment. Utilization of the latest wireless technology allows complete freedom to choose different exercises in various training environments.

More information on the offering: https://www.bittium.com/products__services/medical/faros

Further information:

Arto Pietilä
Senior Vice President, Medical Technologies
Tel. +358 40 344 3507

Distribution:
Main media

Bittium

Bittium specializes in the development of reliable, secure communications and connectivity solutions leveraging its 30 year legacy of expertise in advanced radio communication technologies. Bittium provides innovative products and services, customized solutions based on its product platforms and R&D services. Complementing its communications and connectivity solutions, Bittium offers proven information security solutions for mobile devices and portable computers. From November 2016 onwards, Bittium offers its customers also healthcare technology products and services in biosignal measuring in the areas of cardiology, neurology, rehabilitation, occupational health and sports medicine. Net sales in 2016 was EUR 64.2 million and operating profit was EUR 2.5 million. Bittium is listed on Nasdaq Helsinki. www.bittium.com.

Like up on FACEBOOK


Ebates Coupons and Cash Back

Market quotes are powered by
TradingView.com



Tech Stocks ( GOOG)   (MSFT ) ( AAPL ) (BBRY ) ( gopro )  ( WDC )